For dementia with Lewy bodies (DLB), biomarkers may include the RNA expression levels in small EVs circulating in plasma or altered protein levels in plasma EVs, such as gelsolin and butyrylcholinesterase [111,112,113]. This evidence concerns the gene GSN and Lewy body dementia.